Lauren Wood - Jan 19, 2022 Form 4 Insider Report for PDS Biotechnology Corp (PDSB)

Role
Chief Medical Officer
Signature
/s/ Hillary Yegen, attorney-in-fact
Stock symbol
PDSB
Transactions as of
Jan 19, 2022
Transactions value $
$0
Form type
4
Date filed
1/20/2022, 03:05 PM
Next filing
Jan 6, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PDSB Employee Stock Option (Right to Buy) Award $0 +88.6K $0.00 88.6K Jan 19, 2022 Common Stock 88.6K $6.28 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option, representing a right to purchase a total of 88,600 shares of Common Stock, will become exercisable on January 19, 2023, with 25% vesting on that date and the remaining 75% vesting in equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date, until fully vested on January 19, 2026.